Amgen, Watson Aim For First Joint Oncology Biosimilar In 2017 To Open International Doors
This article was originally published in PharmAsia News
Executive Summary
The deal is a key part of both companies’ plans for aggressive international expansion because they will be able to spread fixed costs and offer robust portfolios to vastly different geographically diverse customers.
You may also be interested in...
In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO
Board member Jeffrey Leiden, who oversaw the commercialization of Humira at Abbott, will succeed Matthew Emmens as Vertex CEO next February.
Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says
Agency interactions with sponsors under BsUFA are not dependent upon opening an IND. Sponsors may be able to demonstrate similarity to an FDA-licensed reference product by bridging to foreign clinical data, Associate Director for Biosimilars Leah Christl says.
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.